The estimated Net Worth of Kenneth L Londoner is at least $7.17 Million dollars as of 13 June 2023. Mr. Londoner owns over 15,600 units of Biosig Technologies Inc stock worth over $1,123,145 and over the last 9 years he sold BSGM stock worth over $1,012,087. In addition, he makes $5,034,850 as Executive Chairman of the Board and Chief Executive Officer at Biosig Technologies Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Londoner BSGM stock SEC Form 4 insiders trading
Kenneth has made over 65 trades of the Biosig Technologies Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 15,600 units of BSGM stock worth $19,344 on 13 June 2023.
The largest trade he's ever made was selling 236,316 units of Biosig Technologies Inc stock on 27 January 2016 worth over $316,663. On average, Kenneth trades about 18,745 units every 31 days since 2015. As of 13 June 2023 he still owns at least 2,507,020 units of Biosig Technologies Inc stock.
You can see the complete history of Mr. Londoner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kenneth Londoner biography
Kenneth L. Londoner serves as Executive Chairman of the Board, Chief Executive Officer of the Company. Mr. Londoner has served as our director since February 2009, as our executive chairman since November 2013 and our chief executive officer since July 2017. He previously served as our chairman and chief executive officer from February 2009 to September 2013. Mr. Londoner previously served as the chief executive officer and president of ViralClear Pharmaceuticals, Inc., a majority-owned subsidiary of the Company (“ViralClear”) from November 2018 and April 2020, and previously served as ViralClear’s chairman of the board of directors from July 2019 and April 2020. Mr. Londoner has been serving as ViralClear’s director since November 2018. Mr. Londoner has served as the managing partner of Endicott Management Partners, LLC, a firm dedicated to assisting emerging growth companies in their corporate development since February 2010. From April 2007 to October 2009, he served as executive vice president – corporate business development and senior director of business development and, from November 2009 to December 2010, he served as a consultant to NewCardio, Inc., a medical device designer and developer. Mr. Londoner also served as a director of chatAND Inc. from January 2012 to April 2015. Mr. Londoner is a co-founder and board member of Safe Ports Holdings, Charleston, South Carolina. Mr. Londoner also served as a director of MedClean Technologies, Inc. from November 2008 to September 2010. Mr. Londoner was an investment officer and co-manager of the Seligman Growth Fund, Seligman Capital Fund, and approximately $2 billion of pension assets at J & W Seligman & Co, Inc. in New York from 1991 to 1997. Mr. Londoner graduated from Lafayette College in 1989 with a degree in economics and finance and received his MBA from New York University’s Leonard N. Stern School of Business in 1994. Londoner’s extensive experience in financial and venture capital matters, as well as his intimate knowledge of ou
What is the salary of Kenneth Londoner?
As the Executive Chairman of the Board and Chief Executive Officer of Biosig Technologies Inc, the total compensation of Kenneth Londoner at Biosig Technologies Inc is $5,034,850. There are no executives at Biosig Technologies Inc getting paid more.
How old is Kenneth Londoner?
Kenneth Londoner is 52, he's been the Executive Chairman of the Board and Chief Executive Officer of Biosig Technologies Inc since 2017. There are 11 older and 1 younger executives at Biosig Technologies Inc. The oldest executive at Biosig Technologies Inc is Dr. Budimir S. Drakulic Ph.D., 71, who is the Chief Scientist.
What's Kenneth Londoner's mailing address?
Kenneth's mailing address filed with the SEC is C/O BIOSIG TECHNOLOGIES, INC., 55 GREENS FARMS ROAD, WESTPORT, CT, 06880.
Insiders trading at Biosig Technologies Inc
Over the last 9 years, insiders at Biosig Technologies Inc have traded over $1,778,587 worth of Biosig Technologies Inc stock and bought 1,345,515 units worth $2,296,289 . The most active insiders traders include Kenneth L Londoner, Asher Holzer, and Jerome B Zeldis. On average, Biosig Technologies Inc executives and independent directors trade stock every 24 days with the average trade being worth of $11,433. The most recent stock trade was executed by Kenneth L Londoner on 13 June 2023, trading 15,600 units of BSGM stock currently worth $19,344.
What does Biosig Technologies Inc do?
biosig technologies, inc. (otcqb: bsgm) is a medical device company that is developing a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (ep) marketplace. led by a proven management team and a veteran, independent board of directors, minneapolis-based biosig is preparing to commercialize its pure ep system.
What does Biosig Technologies Inc's logo look like?
Complete history of Mr. Londoner stock trades at Biosig Technologies Inc
Biosig Technologies Inc executives and stock owners
Biosig Technologies Inc executives and other stock owners filed with the SEC include:
-
Kenneth Londoner,
Executive Chairman of the Board, Chief Executive Officer -
Steven Chaussy,
Chief Financial Officer -
Kenneth L. Londoner M.B.A., MBA,
Founder, CEO & Exec. Chairman -
Samuel Navarro,
Independent Director -
Jeffrey O'Donnell,
Lead Independent Director -
Martha Pease,
Independent Director -
Andrew Filler,
Independent Director -
David Weild,
Independent Director -
Patrick Gallagher,
Independent Director -
Donald Foley,
Independent Director -
Anthony Zook,
Director -
Manasi Patwardhan,
Director of Strategic Planning -
Olivier Chaudoir,
Senior Director of Marketing -
Julie Stephenson,
Vice President - Clinical Affairs, Senior Director of Clinical Affairs -
Andrew Ballou,
Vice President - Investor Relations -
John Kowalski,
Vice President - Sales -
John Sieckhaus,
Chief Operating Officer -
Gray Fleming,
Chief Commercial Officer -
Steven Chaussy,
Chief Financial Officer -
Natasha Drapeau,
Exec. VP -
Brenda Castrodad,
Director of HR -
Lora Mikolaitis,
VP of Admin. -
Dr. Budimir S. Drakulic Ph.D.,
Chief Scientist -
Steven Eric Abelman,
Director -
Steve Chaussy,
Chief Financial Officer -
Roy T Tanaka,
Director -
Lora Mikolaitis,
10% owner -
Seth H. Z. Fischer,
Director -
Joseph Rafferty,
Chief Commercialization Offcr -
Jerome B Zeldis,
Director -
Asher Holzer,
Director -
Gregory D Cash,
President and CEO -
James L Klein,
Director -
James J Barry,
Director -
John Sieckhaus,
Chief Operating Officer -
Gray Fleming,
Chief Commercial Officer -
Steven J Buhaly,
Chief Financial Officer -
Frederick Hrkac,
Director -
Donald Browne,
Director -
Christopher Allen Baer,
Director